Admission DWI demonstrates multifocal areas of acute ischemic injury in poor grade SAH patients. These ischemic lesions may be related to transient intracranial circulatory arrest, acute vasoconstriction, microcirculatory disturbances, or decreased cerebral perfusion from neurogenic cardiac dysfunction. Ischemic brain injury in poor grade SAH may be a feasible target for acute resuscitation strategies.

Background: Background:Patients with thalassemia syndromes or sickle cell disease receiving regular blood transfusions may experience iron overload. Currently, 3 iron chelators are approved for clinical use: deferoxamine administered parenterally (DFO), oral deferiprone (DFP), and oral deferasirox (DFX). Combination therapy of DFP was approved by the European Medicines Agency in 2016, and recent British Society for Haematology guidelines state that DFP+DFX is highly effective. Combination therapy is commonly used in patients who do not adequately respond to monotherapy, have increased iron overload in the heart or liver, or have dose-dependent toxicity, but there is a need to understand which combination therapy to initiate, and when to do so.